Aihong Yang 
,
Yan Ge,
Panpan Yang,
Yuqi Xin,
Chenlu Zhang,
Feixue Xu,
Jiao Yang
For correspondence:- Aihong Yang Email: aihongyang1@msn.com
Accepted: 14 August 2023 Published: 31 October 2023
Citation: Yang A, Ge Y, Yang P, Xin Y, Zhang C, Xu F, et al. Nectin-3 and Nectin-4: potential prognostic biomarkers for therapeutic targeting of cancer. Trop J Pharm Res 2023; 22(10):2235-2241 doi: 10.4314/tjpr.v22i10.27
© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Nectin-3 and nectin-4 belong to the immunoglobulin (Ig) superfamily, and are Ca2+-independent homophilic cell adhesion molecules. Nectin-3 is ubiquitous in adult tissues, and it enhances normal levels of synaptic formation. In contrast, nectin-4 is weakly-to-moderately expressed in normal human tissues. In recent years, studies have shown that nectin-3 is highly expressed in the nervous system. Moreover, it is associated with poor prognostic factors in distant metastases and malignant tumors with high vascular invasion such as pancreatic, lung and breast cancers. In particular, nectin-4 is overexpressed in various malignant tumors, and it is associated with proliferation, angiogenesis, metastasis, drug resistance, tumor relapse, DNA repair, cancer stemness, and poor prognosis. Unlike nectin-3, nectin-4 has become a potential prognostic biomarker and specific therapeutic target for cancer as there is no consensus on the significance of abnormal ex
Archives
News Updates
Fulltext in PDF